top of page

知識資源中心

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

患者故事

透過液體活檢實現轉移性乳癌的個人化治療｜Dr. Shane Dormady

患者故事

2026年6月11日

透過液體活檢實現轉移性乳癌的個人化治療｜Dr. Shane Dormady

閱讀更多
透過液體活檢實現轉移性乳癌的個人化治療｜Dr. Shane Dormady
克隆性造血在個人化風險評估中的新興角色｜Dr. Raj Patel

患者故事

2026年6月2日

克隆性造血在個人化風險評估中的新興角色｜Dr. Raj Patel

閱讀更多
克隆性造血在個人化風險評估中的新興角色｜Dr. Raj Patel
透過液體活檢推動精準癌症治療方案的選擇｜Gilberto Lopes醫師

患者故事

2025年12月19日

透過液體活檢推動精準癌症治療方案的選擇｜Gilberto Lopes醫師

閱讀更多
透過液體活檢推動精準癌症治療方案的選擇｜Gilberto Lopes醫師

論文

Clinical utility of cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA) next generation sequencing (NGS) for diagnosis and treatment of leptomeningeal metastasis (LM) in patients with non-small cell lung cancer (NSCLC): a multi-centre retrospective study

論文

2025年12月1日

Clinical utility of cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA) next generation sequencing (NGS) for diagnosis and treatment of leptomeningeal metastasis (LM) in patients with non-small cell lung cancer (NSCLC): a multi-centre retrospective study

閱讀更多
Clinical utility of cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA) next generation sequencing (NGS) for diagnosis and treatment of leptomeningeal metastasis (LM) in patients with non-small cell lung cancer (NSCLC): a multi-centre retrospective study
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population

論文

2025年11月13日

High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population

閱讀更多
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population
Predictive Model for Mortality Risk Stratification Using Laboratory Biomarkers in Singaporeans

論文

2025年11月12日

Predictive Model for Mortality Risk
Stratification Using Laboratory
Biomarkers in Singaporeans

閱讀更多
Predictive Model for Mortality Risk Stratification Using Laboratory Biomarkers in Singaporeans

臨床見解

The Right Signal at the Right Time: Liquid Biopsy Trends From ASCO 2026

文章

2026年7月22日

The Right Signal at the Right Time: Liquid Biopsy Trends From ASCO 2026

閱讀更多
The Right Signal at the Right Time: Liquid Biopsy Trends From ASCO 2026
MCED Tests: Promise, Limitations, and 3 Questions Worth Asking

文章

2026年7月8日

MCED Tests: Promise, Limitations, and 3 Questions Worth Asking

閱讀更多
MCED Tests: Promise, Limitations, and 3 Questions Worth Asking
Why Cancer Prevention Begins With Longevity Medicine

文章

2026年7月1日

Why Cancer Prevention Begins With Longevity Medicine

閱讀更多
Why Cancer Prevention Begins With Longevity Medicine
Cancer Risk Testing vs. Cancer Screening: What's the Difference?

文章

2026年6月24日

Cancer Risk Testing vs. Cancer Screening: What's the Difference?

閱讀更多
Cancer Risk Testing vs. Cancer Screening: What's the Difference?
Clonal Hematopoiesis: The Somatic Risk Factor Hiding in Plain Sight

文章

2026年6月17日

Clonal Hematopoiesis: The Somatic Risk Factor Hiding in Plain Sight

閱讀更多
Clonal Hematopoiesis: The Somatic Risk Factor Hiding in Plain Sight
When the Scan is Clear: How MRD is Changing Cancer Surveillance After Treatment

文章

2026年6月10日

When the Scan is Clear: How MRD is Changing Cancer Surveillance After Treatment

閱讀更多
When the Scan is Clear: How MRD is Changing Cancer Surveillance After Treatment
When ctDNA Falls Short: The Case for ctRNA in Liquid Biopsy

文章

2026年6月3日

When ctDNA Falls Short: The Case for ctRNA in Liquid Biopsy

閱讀更多
When ctDNA Falls Short: The Case for ctRNA in Liquid Biopsy
Unlocking Treatment Options for Brain Cancers Using Cerebrospinal Fluid

文章

2026年5月26日

Unlocking Treatment Options for Brain Cancers Using Cerebrospinal Fluid

閱讀更多
Unlocking Treatment Options for Brain Cancers Using Cerebrospinal Fluid
Why “Early Detection” Is Not the Same as “Screening”

文章

2026年5月19日

Why “Early Detection” Is Not the Same as “Screening”

閱讀更多
Why “Early Detection” Is Not the Same as “Screening”

最新消息

Why Dr Eric Topol Calls CHIP a Primary Cardiovascular Risk Driver

最新消息

2026年3月18日

Why Dr Eric Topol Calls CHIP a Primary Cardiovascular Risk Driver

閱讀更多
Add
Lucence, DxD Hub and NCCS Launch S$6M Research Collaboration to Advance Cancer Diagnostics Through AI and Patient-Centric Research

最新消息

2026年3月13日

Lucence, DxD Hub and NCCS Launch S$6M Research Collaboration to Advance Cancer Diagnostics Through AI and Patient-Centric Research

閱讀更多
Add
Lucence and Partners Pathology Collaborate to Advance Cancer Diagnostics in Malaysia

最新消息

2026年3月5日

Lucence and Partners Pathology Collaborate to Advance Cancer Diagnostics in Malaysia

閱讀更多
Add

網上研討會

Mayo Clinic Laboratories: The next generation of liquid biopsy testing

網上研討會

2025年11月12日

Mayo Clinic Laboratories: The next generation of liquid biopsy testing

Visit
Mayo Clinic Laboratories: The next generation of liquid biopsy testing
New Frontiers in Liquid Biopsy for Lung Cancer

網上研討會

2021年6月30日

New Frontiers in Liquid Biopsy for Lung Cancer

閱讀更多
New Frontiers in Liquid Biopsy for Lung Cancer

案例研究

LiquidHALLMARK® ctRNA Detects ALK Fusion in Lung Cancer

案例研究

2025年11月12日

LiquidHALLMARK® ctRNA Detects ALK Fusion in Lung Cancer

閱讀更多
LiquidHALLMARK® ctRNA Detects ALK Fusion in Lung Cancer
bottom of page